D. Boral Capital Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $2.00 target price on the stock. D. Boral Capital's price target indicates a potential upside of 238.93% from the stock's current price.

Separately, HC Wainwright upped their price objective on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th.

Lineage Cell Therapeutics Trading Up 14.6 %

Shares of LCTX stock traded up $0.08 on Friday, reaching $0.59. The company had a trading volume of 5,577,547 shares, compared to its average volume of 8,868,523. Lineage Cell Therapeutics has a one year low of $0.48 and a one year high of $1.61. The stock has a market capitalization of $130.07 million, a P/E ratio of -4.92 and a beta of 1.16.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LCTX. Defender Capital LLC. lifted its position in shares of Lineage Cell Therapeutics by 0.6% during the third quarter. Defender Capital LLC. now owns 5,002,198 shares of the company's stock valued at $4,528,000 after purchasing an additional 29,223 shares in the last quarter. Raffles Associates LP lifted its position in shares of Lineage Cell Therapeutics by 3.4% during the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company's stock worth $4,081,000 after buying an additional 150,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Lineage Cell Therapeutics by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company's stock worth $3,331,000 after buying an additional 83,274 shares during the last quarter. State Street Corp grew its holdings in shares of Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company's stock valued at $2,361,000 after acquiring an additional 45,483 shares in the last quarter. Finally, MAI Capital Management increased its position in shares of Lineage Cell Therapeutics by 2.2% during the third quarter. MAI Capital Management now owns 1,674,679 shares of the company's stock valued at $1,516,000 after acquiring an additional 35,907 shares during the last quarter. Institutional investors and hedge funds own 62.47% of the company's stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.